ArticleAsian Pacific journal of cancer prevention : APJCP2020
Comparative Analysis of Breast Cancer Incidence Rates between Australia and Japan: Screening Target Implications.
Article in Asian Pacific journal of cancer prevention : APJCP, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Clinical Information and Prognosis of High-risk Luminal Breast Cancer Subjects Eligible for the MonarhE Study.JMA journal · 2025Article
- The burden and long-term trends of breast cancer by different menopausal status in China.Journal of the National Cancer Center · 2024Article
- Overall survival in Japanese patients with ER+/HER2- advanced breast cancer treated with first-line palbociclib plus letrozole.Breast cancer (Tokyo, Japan) · 2024Article
- Intercontinental comparison of women with breast cancer treated by oncologists in Europe, Asia, and Latin America: a retrospective study of 99,571 patients.Journal of cancer research and clinical oncology · 2023Article
- Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan.Breast cancer (Tokyo, Japan) · 2023Article
- Article
- Association between body mass index and incidence of breast cancer in premenopausal women: a Japanese nationwide database study.Breast cancer research and treatment · 2022Article
- Global Burden of Female Breast Cancer: Age-Period-Cohort Analysis of Incidence Trends From 1990 to 2019 and Forecasts for 2035.Frontiers in oncology · 2022Article
- Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels.Cancer management and research · 2022Article
- Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020.Cancer communications (London, England) · 2021Article
- Breast Cancer Statistics in Korea, 2018.Journal of breast cancer · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe purpose of this analysis was to compare the age-specific incidence rates (ASIRs) of breast cancer in Australia and Japan to determine the appropriateness of national screening target age groups.
methodsThe paper is based on secondary sources of data. The ASIRs in 2006-2015 were collected from the Australian Institute of Health and Welfare (AIHW) and the National Cancer Center Japan. Descriptive analysis was performed for a comparison of ASIRs between Australia and Japan by age and over time. Percentage change, rolling average and risk ratio were calculated for further analysis.
resultsIn Australia, ASIRs rose sharply from age 40 years and peaked at 65-69 years. Japanese data demonstrated a considerable increase each year and two peaks were recorded, at ages 45-49 and 60-64. The ASIRs after age 65 decreased with age in Japan but increased with age in Australia. The ASIRs of women aged 40-49 was lowest among Australian women and the highest among Japanese women, while they had similar ASIRs in the direct comparative analysis.
conclusionsThe screening age range of Australian and Japanese national breast cancer screening guidelines covers incidence peak ages in each country and therefore provides benefit for cancer screening. Our findings also indicated that further evidence is required to investigate the inclusion of Japanese migrant women in Australia aged 40-49 years into the screening target and the BCI rates of post-migrant women in Australia as different migrant groups have different ASIRs. This is to ensure that the groups of women with the highest cancer incidence are appropriately covered in screening programs.<br />.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.